Login to Your Account



Search

Search results

Pharma: Clinic roundup

Boehringer Ingelheim GmbH , of Ingelheim, Germany, reported results from the phase III STARTVerso 4 trial in patients co-infected with hepatitis C virus (HCV) and HIV, showing that HCV cure 12 weeks (SVR12) after the conclusion of treatment was ach ...

BioWorld Today - Staff - 2014-03-07 01:00 - 0 comments - 0 attachments

Pharma: clinic roundup

Roche AG , of Basel, Switzerland, presented new data from the LUTE/VERSE phase IIb studies investigating lebrikizumab in patients with severe uncontrolled asthma. The data showed that asthma attacks were reduced by 60 percent in lebrikizumab-trea ...

BioWorld Today - Staff - 2014-03-06 01:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Janssen Pharmaceutica NV , of Beerse, Belgium, part of Johnson & Johnson, reported results from the PROSIPAL (Prevention of Relapse With Oral Antipsychotics Versus Injectable Paliperidone Palmitate) study at the European Congress of Psychiatry ...

BioWorld Today - Staff - 2014-03-05 01:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Boehringer Ingelheim Corp. , of Ridgefield, Conn., part of Boehringer Ingelheim GmbH, presented data from phase III studies of tiotropium delivered via the Respimat inhaler in mild, moderate and severe asthma patients at the 2014 American Academy of ...

BioWorld Today - Staff - 2014-03-04 01:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Eisai Inc. , of Woodcliff Lake, N.J., said it started a phase III trial to compare the efficacy, safety and tolerability of eribulin mesylate to standard weekly paclitaxel as first- or second-line treatment for HER2-negative locally recurrent or meta ...

BioWorld Today - Staff - 2014-02-28 01:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Bristol-Myers Squibb Co. , of New York, and the Institute of Research in Immunology and Cancer in Montreal identified a molecule acting on a “novel therapeutic target” that was undisclosed. (BioWorld-Today-2014-02-27) ...

BioWorld Today - Staff - 2014-02-27 01:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Baxter International Inc. , of Deerfield, Ill., said it started dosing patients with malignant solid tumors in a Phase I study of a fully human recombinant anti-macrophage migration inhibitory factor (MIF) monoclonal antibody. (BioWo ...

BioWorld Today - Staff - 2012-09-06 00:00 - 0 comments - 0 attachments

Pharma: clinic roundup

Janssen Research & Development LLC , of Raritan, N.J., part of Johnson & Johnson, started the CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation) phase III, global, multicenter study of Invok ...

BioWorld Today - Staff - 2014-02-24 01:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Bayer AG , of Leverkusen, Germany, said its Bayer Healthcare unit began enrolling patients in the phase III COAST trial of Stivarga (regorafenib) in colorectal cancer (CRC) patients with resected liver metastases. (BioWorld-Today-2014-02-21) ...

BioWorld Today - Staff - 2014-02-21 01:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Eli Lilly and Co. , of Indianapolis, said the randomized, double-blind, global phase III REVEL study of ramucirumab in combination with chemotherapy in second-line non-small-cell lung cancer (NSCLC) showed a statistically significant improvement in t ...

BioWorld Today - Staff - 2014-02-20 01:00 - 0 comments - 0 attachments